Media
For media enquiries please contact:
media@evivebiotech.com
Latest Press Release
Evive Biotech and Dr. Xiao Qiang Yan Form Joint Venture to Further Develop Bi-specific Antibody Platform ITab
- 10 February 2021
Evive Biotech Announces First Patient Dosed in Phase 2 Study to Evaluate the Efficacy and Safety of F-652 in Patients with Moderate to Severe COVID-19
- 2 February 2021
Mucosal Immunology Article Details IL-22’s Critical Role in Maturation of Certain Epithelial Cells
- 15 January 2021
Evive Biotech Meets Primary and Secondary Endpoints in Global Phase III Clinical Trial for Their Novel Chemotherapy-induced Neutropenia Treatment
- 7 July 2020
Evive Successfully Concludes China Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia
- 6 January 2020
Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease
- 22 October 2019
Evive Announces Initiation of a Phase I Trial of A-319 to Treat Patients with B Cell Malignancies
- 9 September 2019
Evive Receives Investigative New Drug (IND) Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies
- 19 November 2018
Evive’s F-652 Shows Positive Results in “An Open Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy in Patients with Alcoholic Hepatitis”
- 19 November 2018
